TSHA (Taysha Gene Therapies) Total Stockholders Equity: $387.27 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSHA Taysha Gene Therapies Inc TSHA
33 GF Score
Price $5.02
GF Value $0.53
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Taysha Gene Therapies Total Stockholders Equity?

Taysha Gene Therapies TSHA -2.71% 33 Total Stockholders Equity is $387.27 Mil as of Jun. 2026. GuruFocus rates TSHA with a GF Score™ of 33/100 and a GF Value™ of $0.53 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Taysha Gene Therapies's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $387.27 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Taysha Gene Therapies's Book Value per Share for the quarter that ended in Jun. 2026 was $1.19. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Taysha Gene Therapies's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.15.

Taysha Gene Therapies  (NAS:TSHA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Taysha Gene Therapies's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(387.266-0)/325.302
=1.19

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Taysha Gene Therapies's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.163 + 55.551) / 387.266
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taysha Gene Therapies Total Stockholders Equity Related Terms

Taysha Gene Therapies Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Taysha Gene Therapies's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taysha Gene Therapies Total Stockholders Equity Chart

Taysha Gene Therapies Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial 95.38 0.95 74.94 71.53 246.94

Taysha Gene Therapies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 248.73 218.99 246.94 211.94 387.27
TSHA
33GF Score
Taysha Gene Therapies Inc TSHA
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $387.27 Mil mean?
Taysha Gene Therapies (TSHA) has a Total Stockholders Equity of $387.27 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Taysha Gene Therapies and its competitors.
Is Taysha Gene Therapies' Total Stockholders Equity too high?
Taysha Gene Therapies' current Total Stockholders Equity is $387.27 Mil. Overall, Taysha Gene Therapies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' Total Stockholders Equity compare to KARD and GHRS?
Taysha Gene Therapies' Total Stockholders Equity of $387.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Taysha Gene Therapies and its competitors. Taysha Gene Therapies's current Total Stockholders Equity is $387.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.53, compared to a current price of $5.02 — trading 847.2% above its estimated fair value. The current Total Stockholders Equity is $387.27 Mil. Taysha Gene Therapies' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current Total Stockholders Equity is $387.27 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taysha Gene Therapies (TSHA) Overvalued in 2026?

Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued. The current stock price of $5.02 is trading 847.2% above its estimated GF Value™ of $0.53. GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.

Key valuation signals for TSHA:

  • Total Stockholders Equity: $387.27 Mil
  • GF Value™: $0.53 vs. price of $5.02 (847.2% above fair value)
  • GF Score™: 33/100 with 2 warning signs

No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taysha Gene Therapies Business Description

Address 3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
33GF Score

Get the complete analysis for TSHA

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.02
Price
$0.53
GF Value